Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Launch Of New BioInterfaces Research Program
With an annual budget of 20 Million Euro, 67 research groups develop new tools to control cells
generic viagra online
Care Management Reduces Depression And Suicidal Thoughts In Older Primary Care Patients
Depression in older adults too often goes unrecognized and untreated, resulting in untold misery, worsening of medical illness, and early death. A new study has identified one important remedy: Adding a trained depression care manager to primary care practices can increase the number of patients receiving treatment, lead to a higher remission rate of depression, and reduce suicidal thoughts.
News of the day
First Free Heart Testing Tour Of England
A new national campaign aiming to reduce the number of undiagnosed heart conditions will visit 12 destinations in England throughout May and June. The CRY Philips Test My Heart Tour 09 is the first free tour of its kind in England and has been made possible by charity CRY, health and well-being company Philips, through the fundraising efforts of families whose lives have been affected by Sudden Death Syndrome (SDS) or Sudden Cardiac Death (SCD), and the Gwyneth Forrester Trust. The tour aims to test over 3,000 14-35 year olds hearts to identify heart conditions which could potentially prove fatal if left untreated. To book a free appointment at one of the 12 tour locations simply go to http://www.testmyheart.org
Diagnostics

Stentys Establishes U.S. Operations In Princeton, N.J.

Medical device pioneer Stentys announced that it has established U.S. operations in Princeton, N.J., where the Company will focus its R&D efforts. The Princeton operation will be the cornerstone of the Company"s efforts when seeking FDA clearance to market its self-expanding and disconnectable stent platform. "Establishing U.S. operations is a major milestone for Stentys" future commercial launch," said CEO and co-founder, Gonzague Issenmann. "This is a very exciting time as we are also establishing a radically innovative and improved treatment for acute coronary syndrome (ACS)." ACS procedures represent half of the $5 billion coronary stenting market. But today"s treatment with balloon-expandable stents is plagued by a high incidence of malapposition, a major predictor of stent thrombosis, and that caps the market at a lower value. "Stentys" platform solves malapposition thanks to its self-expanding feature that ensures optimal apposition in the critical hours and days after the procedure. The stent is constantly applied to the vessel surface during thrombus and vessel spasm relief, as demonstrated in the successful initial clinical experience," explained Issenmann. Stentys


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009